These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The historical development of cancer chemotherapy. Burchenal JH Semin Oncol; 1977 Jun; 4(2):135-46. PubMed ID: 327552 [No Abstract] [Full Text] [Related]
3. [Chemotherapy of tumor disease: past and future]. Gross R; Claus O Med Welt; 1982 Nov; 33(44):1531-8. PubMed ID: 6757639 [No Abstract] [Full Text] [Related]
4. Historical development and future promise of the nitrosoureas as anticancer agents. Schabel FM Cancer Chemother Rep 3; 1973 May; 4(3):3-6. PubMed ID: 4584035 [No Abstract] [Full Text] [Related]
5. Proceedings of the Workshop on Antimetabolites and the Central Nervous System (New York, NY, February 2-3, 1976): Looking backward while going forward. Stock CC Cancer Treat Rep; 1977 Jul; 61(4):509-11. PubMed ID: 328144 [No Abstract] [Full Text] [Related]
6. Introduction: a history of the progress of anticancer chemotherapy. Calvert AH Cancer Surv; 1989; 8(3):493-509. PubMed ID: 2701082 [No Abstract] [Full Text] [Related]
7. Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. Griswold DP Cancer Treat Rep; 1986 Jan; 70(1):81-6. PubMed ID: 3943116 [No Abstract] [Full Text] [Related]
8. Chemotherapy of colorectal cancer: history and new themes. Bertino JR Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-3-S18-7. PubMed ID: 9420015 [TBL] [Abstract][Full Text] [Related]
9. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210. Góra-Tybor J; Robak T; Warzocha K; Grieb P Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633 [TBL] [Abstract][Full Text] [Related]
10. Experimental models and their clinical correlations. Carter SK; Goldin A Natl Cancer Inst Monogr; 1977 Mar; (45):63-74. PubMed ID: 927496 [No Abstract] [Full Text] [Related]
12. Screening data from the Caner Chemotherapy National Service Center Screening Laboratories. XXIX. Leiter J; Abbott BJ; Schepartz SA Cancer Res; 1965 Dec; 25(11 Pt 2):1779-2061. PubMed ID: 5856668 [No Abstract] [Full Text] [Related]
13. Potentially useful combinations of chemotherapy detected in mouse tumor systems. Kline I Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187 [No Abstract] [Full Text] [Related]
14. Interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX). Jung KH; Kil SY; Choi IK; Seo JH; Shin C; Kim YS; Kim JH Int J Tuberc Lung Dis; 2006 Oct; 10(10):1181-2. PubMed ID: 17044215 [No Abstract] [Full Text] [Related]
15. [Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma]. MMW Fortschr Med; 2002 Oct; 144(41):61. PubMed ID: 12474374 [No Abstract] [Full Text] [Related]
16. An outline of cancer chemotherapy. Connors TA Rev Roum Inframicrobiol; 1971; 8(3):135-51. PubMed ID: 5152643 [No Abstract] [Full Text] [Related]
17. [Models and methods used for the selection of antitumor preparations in the USSR and abroad]. Sof'ina ZP Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284 [No Abstract] [Full Text] [Related]
18. [Angiogenesis as a target for antitumor actions]. Ushmorov AG; Aleksandrov VA Vopr Onkol; 1989; 35(3):263-70. PubMed ID: 2468258 [No Abstract] [Full Text] [Related]
19. [Chemotherapy cancer treatment during the past sixty years]. Furue H Gan To Kagaku Ryoho; 2003 Oct; 30(10):1404-11. PubMed ID: 14584272 [TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy: considerations for design and analysis. Lloyd HH Cancer Chemother Rep 2; 1974 Mar; 4(1):157-65. PubMed ID: 4826495 [No Abstract] [Full Text] [Related] [Next] [New Search]